By admin 
Cambridge, MA – September 22, 2026 – New data emerging from Viking Therapeutics’ Phase 2 clinical trial for its investigational obesity drug, VK2735, indicates that participants successfully maintained significant weight loss even after transitioning from a weekly injection regimen to less frequent bi-weekly or monthly dosing. These findings, published today, could substantially bolster Viking’s competitive stance in the burgeoning and fiercely contested market for obesity therapeutics, as noted by leading industry analysts. The trial’s success in demonstrating sustained efficacy with extended dosing intervals addresses a critical unmet need in chronic weight management, offering a potential pathway to improved patient adherence and long-term treatment outcomes.
The preliminary results highlight a pivotal development for VK2735, a dual agonist targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This mechanism of action is similar to Eli Lilly’s blockbuster drug Zepbound (tirzepatide), which has rapidly captured a significant share of the global anti-obesity market. However, Viking’s trial suggests a potential advantage in dosing frequency, a factor that could differentiate VK2735 in a landscape currently dominated by weekly injectable therapies.
Addressing the Adherence Challenge in Obesity Management
The landscape of obesity treatment has undergone a revolutionary transformation with the advent of GLP-1 and dual GLP-1/GIP receptor agonists. Drugs such as Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) have redefined the clinical possibilities for patients struggling with obesity, enabling many to achieve unprecedented double-digit percentage weight reductions. These therapies work by mimicking natural hormones that regulate appetite, satiety, and glucose metabolism, leading to reduced food intake and improved metabolic health.
Despite their profound efficacy, current GLP-1-based therapies face certain limitations that impact their long-term effectiveness and patient experience. Foremost among these are the gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation, which can be significant enough to lead some patients to discontinue treatment. Furthermore, the chronic nature of obesity requires lifelong management, and the necessity of weekly injections or daily pills for existing treatments can pose a substantial adherence challenge. Studies have consistently shown that adherence rates for chronic medications, even highly effective ones, tend to decline over time, undermining the potential for sustained weight loss and associated health benefits. This "treatment persistence" issue remains a significant hurdle for patients and clinicians alike.
Viking Therapeutics has strategically positioned VK2735 as an alternative treatment strategy designed to overcome some of these existing limitations. The Phase 2 trial, known as VENTURE-DM, investigated the efficacy and safety of VK2735, not only during an initial induction phase but critically during a subsequent maintenance phase with reduced dosing frequency.
Detailed Trial Findings and Methodology
The Phase 2 trial initiated an "induction" phase where enrollees were gradually titrated up to weekly doses of VK2735 at 15 mg, 17.5 mg, 20 mg, or 22.5 mg over 21 weeks. During this period, participants demonstrated robust weight loss, ranging from an average of 16% in the 15 mg group to an impressive 19% in the 20 mg group. These figures are highly competitive with existing market leaders and underscore the potent weight-reducing capabilities of VK2735.
Following the 21-week induction phase, a subset of participants transitioned into a maintenance phase for an additional 12 weeks. During this crucial period, patients were switched to either bi-weekly (every-other-week) or monthly injections. The objective was to assess whether the achieved weight loss could be sustained with less frequent administration. The results were highly encouraging: average weight loss maintenance ranged from 82% to 97%, depending on the specific dosing strategy employed in the maintenance phase.
Breaking down these figures, Viking reported that for the larger group of all enrollees who transitioned to every-other-week dosing, the average weight loss maintenance was a remarkable 90%. For those in the monthly dosing group, the figure stood at 85%. These percentages indicate that the vast majority of the weight lost during the intensive induction phase was preserved even when the frequency of injections was significantly reduced. Such high maintenance rates with extended dosing intervals represent a substantial clinical achievement and a potential game-changer for patient convenience and long-term adherence.
Dr. Louis Aronne, a distinguished professor of metabolic research at Weill-Cornell Medical College and former president of The Obesity Society, underscored the significance of these findings. In a statement provided by Viking, Dr. Aronne commented, "These results are important as they provide a basis for improved dosing flexibility for both clinicians and their patients. Flexibility for patients and providers is paramount for achieving treatment persistence leading to the long-term benefits of weight control, and these results are an important step in that direction." His statement highlights the expert community’s recognition of dosing flexibility as a critical factor in the real-world success of chronic disease management.
Crucially, the trial also reported favorable safety and tolerability profiles during both phases. Viking noted low rates of discontinuations attributable to side effects. Only one discontinuation occurred during the induction phase, another in the every-other-week dosing group, and three more in the monthly dosing cohort. Furthermore, the frequency of gastrointestinal side effects, a common concern with GLP-1-based therapies, was not "meaningfully different" during the maintenance phase compared to the induction phase, suggesting that reducing dosing frequency did not exacerbate these issues. This robust safety profile, combined with sustained efficacy, strengthens the overall appeal of VK2735.
The Broader Context: A Rapidly Evolving Market
The global market for obesity drugs is projected to reach hundreds of billions of dollars in the coming decade, driven by rising obesity rates worldwide and the increasing recognition of obesity as a chronic disease requiring medical intervention. Novo Nordisk and Eli Lilly have established early dominance with their respective GLP-1 and dual GLP-1/GIP agonists, Wegovy and Zepbound. However, the sheer size and growth potential of this market continue to attract intense competition from numerous pharmaceutical companies, including Viking Therapeutics, Amgen, Pfizer, and others, all vying to introduce differentiated therapies.
Current therapies, while highly effective, demand continuous adherence. Patients typically regain a significant portion of their lost weight if they discontinue treatment. This necessitates a long-term commitment, which can be challenging for various reasons, including cost, side effects, and the psychological burden of chronic medication. A drug that offers similar efficacy with less frequent dosing could significantly improve patient quality of life and enhance real-world adherence, thereby leading to better health outcomes for a larger population.
The mechanism of VK2735, as a dual GLP-1/GIP agonist, positions it directly against Zepbound. GLP-1 agonists primarily work by slowing gastric emptying, increasing insulin secretion in a glucose-dependent manner, and reducing glucagon secretion, leading to improved glycemic control and enhanced feelings of fullness. GIP, on the other hand, also plays a role in glucose metabolism and energy balance, and combining the effects of both hormones is believed to lead to synergistic benefits in weight loss and metabolic improvements. Viking’s success in achieving comparable weight loss to existing dual agonists, combined with its differentiated dosing profile, could make it a formidable contender.
Timeline and Future Implications
Looking ahead, Viking Therapeutics is already well into the next critical stage of development. The company announced that the Phase 3 clinical trials for VK2735 were fully enrolled as of November 2025. These pivotal trials are essential for gathering the extensive data required for regulatory approval and will further evaluate the long-term efficacy and safety of the drug in a larger patient population. It is noteworthy that the Phase 3 trials are testing doses only up to 17.5 mg weekly, which suggests that Viking is focusing on a well-tolerated and effective dose range for broader market introduction. The successful completion of Phase 3 trials and subsequent regulatory submission would pave the way for VK2735 to enter the market, potentially within the next few years.
The implications of Viking’s findings extend beyond just competitive positioning. For patients, the prospect of maintaining weight loss with bi-weekly or monthly injections could represent a significant improvement in convenience and quality of life. Reduced injection frequency might alleviate some of the psychological burdens associated with chronic treatment and could lead to higher rates of sustained adherence, ultimately translating into better long-term health benefits, including reduced risk of obesity-related comorbidities such such as type 2 diabetes, cardiovascular disease, and certain cancers.
For healthcare systems, improved adherence could mean more effective population-level management of obesity, potentially reducing the overall economic burden associated with the disease. Less frequent dosing could also have logistical benefits, simplifying prescription refills and patient education.
From an investment perspective, these positive Phase 2 results are likely to be met with enthusiasm. Analysts may revise their models to account for VK2735’s enhanced market potential, potentially leading to increased valuations for Viking Therapeutics. Competitors, particularly Eli Lilly and Novo Nordisk, will undoubtedly be closely monitoring Viking’s progress, as the demand for differentiation in this lucrative market is high. This could spur further innovation in drug delivery mechanisms, formulation, and next-generation compounds designed to offer even greater convenience and efficacy. The race to provide the most effective, safest, and most patient-friendly obesity treatment continues to accelerate, with Viking Therapeutics now firmly establishing itself as a key innovator in this vital therapeutic area.
